Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 6 | 2018 | 162 | 0.550 |
Why?
|
| Pancreatic Neoplasms | 6 | 2019 | 131 | 0.480 |
Why?
|
| Colorectal Neoplasms | 5 | 2018 | 208 | 0.440 |
Why?
|
| Hepatectomy | 5 | 2018 | 66 | 0.370 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 301 | 0.340 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 29 | 0.310 |
Why?
|
| Postoperative Complications | 3 | 2017 | 670 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 20 | 0.200 |
Why?
|
| Communication Barriers | 1 | 2017 | 22 | 0.150 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.150 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 21 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 62 | 0.150 |
Why?
|
| Laparotomy | 1 | 2017 | 32 | 0.150 |
Why?
|
| Risk | 1 | 2017 | 290 | 0.140 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2017 | 43 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 74 | 0.140 |
Why?
|
| Survival Rate | 5 | 2018 | 795 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2004 | 10 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2114 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3121 | 0.100 |
Why?
|
| Vena Cava Filters | 1 | 1991 | 14 | 0.100 |
Why?
|
| Crohn Disease | 1 | 1991 | 25 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 1991 | 46 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 401 | 0.090 |
Why?
|
| Aged | 10 | 2019 | 9510 | 0.090 |
Why?
|
| Hemorrhage | 1 | 1991 | 91 | 0.090 |
Why?
|
| Humans | 16 | 2019 | 29213 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2018 | 3108 | 0.090 |
Why?
|
| Middle Aged | 9 | 2018 | 10868 | 0.090 |
Why?
|
| Male | 11 | 2019 | 17872 | 0.090 |
Why?
|
| Female | 10 | 2019 | 18236 | 0.080 |
Why?
|
| Prognosis | 3 | 2019 | 1363 | 0.070 |
Why?
|
| Telomerase | 1 | 2006 | 21 | 0.070 |
Why?
|
| Camptothecin | 2 | 2005 | 48 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 58 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2005 | 63 | 0.070 |
Why?
|
| Endosonography | 1 | 2006 | 56 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 241 | 0.070 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2004 | 5 | 0.060 |
Why?
|
| Cystadenocarcinoma | 1 | 2004 | 3 | 0.060 |
Why?
|
| Oxyphil Cells | 1 | 2004 | 2 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2004 | 62 | 0.060 |
Why?
|
| Morbidity | 2 | 2017 | 92 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2002 | 19 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2017 | 2027 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 3726 | 0.050 |
Why?
|
| Adult | 6 | 2017 | 8466 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 3547 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2018 | 72 | 0.040 |
Why?
|
| Malpractice | 1 | 2017 | 20 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 53 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 107 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 190 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 231 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 75 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 2413 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2018 | 365 | 0.040 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1996 | 1 | 0.040 |
Why?
|
| Communication | 1 | 2017 | 122 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 169 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 223 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 3265 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 252 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 729 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 525 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1123 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1365 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 56 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1694 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 163 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 440 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1312 | 0.020 |
Why?
|
| Colectomy | 1 | 1991 | 25 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 709 | 0.020 |
Why?
|
| Hematoma | 1 | 1991 | 23 | 0.020 |
Why?
|
| Arteries | 1 | 1991 | 60 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 546 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2008 | 146 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 50 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 172 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 235 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 32 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 24 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 68 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 49 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 38 | 0.020 |
Why?
|
| Diarrhea | 1 | 2005 | 56 | 0.020 |
Why?
|
| Heart Failure | 1 | 1991 | 571 | 0.020 |
Why?
|
| Fatigue | 1 | 2005 | 69 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 281 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 246 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 533 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 493 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2004 | 30 | 0.020 |
Why?
|
| Disease Progression | 1 | 2005 | 572 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 23 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 1 | 2002 | 33 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 174 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 89 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 436 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 641 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1996 | 3 | 0.010 |
Why?
|
| Gastrins | 1 | 1996 | 4 | 0.010 |
Why?
|
| Somatostatin | 1 | 1996 | 10 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1996 | 40 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 140 | 0.010 |
Why?
|
| Insulin | 1 | 1996 | 346 | 0.010 |
Why?
|